Molecular Profile of Breast Cancer in Ugandan Patients With Stage IIB-III Breast Cancer
NCT ID: NCT03518242
Last Updated: 2022-06-08
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE1
100 participants
INTERVENTIONAL
2018-06-06
2022-05-04
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Chemotherapy in Treating Women With Previously Treated Metastatic Breast Cancer
NCT00003236
Combination Chemotherapy and Peripheral Stem Cell Transplantation in Treating Patients With Stage II or Stage IIIA Breast Cancer
NCT00003972
Abiraterone Acetate in Molecular Apocrine Breast Cancer
NCT01842321
Breast Cancer Pathways Program Impact on Patient Shared Decision Making and Experience in Academic and Community Practice
NCT04297384
Fulvestrant in Metastatic Breast Cancer
NCT03591549
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
SPECIMEN COLLECTION: Patients undergo collection of tumor tissue and peripheral blood samples for analysis via next generation sequencing to identify novel pathways in the pathogenesis of breast cancer.
TREATMENT: Patients are invited to participate in a treatment study. Patients receive cyclophosphamide orally (PO) daily on days 1-21, methotrexate PO QD on days 1, 8, and 15, and capecitabine PO twice daily (BID) on days 1-14. Treatment repeats every 21 days for 8 cycles in the absence of disease progression or unacceptable toxicity.
After completion of study, patients are followed up for 24 months.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NA
SINGLE_GROUP
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Treatment (Specimen collection, chemotherapy)
SPECIMEN COLLECTION: Patients undergo collection of tumor tissue and peripheral blood samples for analysis via next generation sequencing to identify novel pathways in the pathogenesis of breast cancer.
TREATMENT: Patients are invited to participate in a treatment study. Patients receive cyclophosphamide PO daily on days 1-21, methotrexate PO QD on days 1, 8, and 15, and capecitabine PO BID on days 1-14. Treatment repeats every 21 days for 8 cycles in the absence of disease progression or unacceptable toxicity.
Cyclophosphamide
Given PO
Methotrexate
Given PO
Capecitabine
Given PO
Biospecimen Collection
Undergo biospecimen collection
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Cyclophosphamide
Given PO
Methotrexate
Given PO
Capecitabine
Given PO
Biospecimen Collection
Undergo biospecimen collection
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Absolute neutrophil count (ANC) \> 1500/mm
* Hemoglobin \> 9 g/dL
* Platelets \>=100,000 cells/mm\^3
* Total bilirubin =\< 1.2 mg/dL
* International normalized ratio (INR) =\< 1.5 x upper limit of normal (ULN)
* Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) =\< 1.5 x ULN
* Serum alkaline phosphatase should be 1.5 x ULN
* Patients with positive hepatitis B or C serologies without known active disease must meet the eligibility requirements for ALT, AST, total bilirubin, INR, activated partial thromboplastin time (aPTT), and alkaline phosphatase on at least two consecutive occasions, separated by at least 1 week
* Adequate renal function with serum creatinine \< 1.5 x ULN
* Premenopausal patients must have a negative serum or urine pregnancy test, including women who have had a tubal ligation and for women less than 12 months after the onset of menopause
* Women of childbearing potential must be willing to use one highly effective form of nonhormonal contraception or two effective forms of nonhormonal contraception by the patient and/or partner and continue its use for the duration of the study treatment
* Left ventricular ejection fraction \>= 50%
* Eastern Cooperative Oncology Group (ECOG) performance status \< 2
* Signed written informed consent
Exclusion Criteria
* Active, unresolved infection or systemic disease (e.g. pulmonary or metabolic disease)
* Patients with active liver disease
* Patients with active cardiac disease, including congestive heart failure (or therapy specifically for congestive heart failure \[CHF\])
* Patients with uncontrolled hypertension (diastolic \>100 mmHg or systolic \> 160 mmHg)
* Known hypersensitivity to any of the drugs
* Significant current illness (including psychiatric illness)
* Any social situations or other conditions that in the opinion of the investigator limit compliance with study requirements
* Calcium imbalance
* Patients that have received treatment with sorividine or brividine (herpex) or any related analogue within 4 weeks prior to starting the investigational product (IP)
* Eye problems
* Patients on any of the following medications: acitretin, azathioprine, Bacillus Calmette Guerin (BCG) (intravesicular), belimumab, deferiprone, diphyrone, etanercept, foscarnet, gimeracil, levetriracetam, natalizumab, pimercrolimus, retinoids, sulfazalazine, tacrolimus tofacitininb
* Patients receiving any anticoagulation (including warfarin)
18 Years
FEMALE
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
GlaxoSmithKline
INDUSTRY
Fred Hutchinson Cancer Center
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Manoj Menon
Role: PRINCIPAL_INVESTIGATOR
Fred Hutchinson Cancer Center
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
New Mulago Hospital
Kampala, , Uganda
Uganda Cancer Institute
Kampala, , Uganda
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
NCI-2018-02609
Identifier Type: REGISTRY
Identifier Source: secondary_id
RG1001403
Identifier Type: OTHER
Identifier Source: secondary_id
8424
Identifier Type: OTHER
Identifier Source: secondary_id
U025
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.